• DNDi - Best Science for the Most Neglected 20 Years
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • COVID-19
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • HELP Helminth Elimination Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi Southern Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
DNDi - Best Science for the Most Neglected 20 Years
  • DNDi - Best Science for the Most Neglected 20 Years
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • COVID-19
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • HELP Helminth Elimination Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi Southern Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home > Press releases

DNDi welcomes new PAHO recommendations for the treatment of leishmaniasis in the Americas

The new guidelines can help national programmes strengthen and expand diagnosis and treatment for people affected by this neglected disease

Home > Press releases

DNDi welcomes new PAHO recommendations for the treatment of leishmaniasis in the Americas

The new guidelines can help national programmes strengthen and expand diagnosis and treatment for people affected by this neglected disease

Lab activities
Rio de Janeiro, Brazil — 29 Jun 2022
Share on twitter
Share on facebook
Share on linkedin
Share on email
Share on print
  • English
    • English
    • Español
    • Português

The Drugs for Neglected Diseases initiative (DNDi) welcomes the publication of new recommendations for the treatment of leishmaniasis in the Americas by the Pan American Health Organization (PAHO).

Leishmaniasis is a neglected tropical disease and serious public health problem. It is endemic in 20 Latin American countries, recording each year an average of around 53,000 new cases of the cutaneous and mucosal forms of the disease and 3,400 cases of visceral leishmaniasis. Transmitted by the bite of sandflies infected with the Leishmania parasite, manifestations of the disease range from single or multiple ulcerated lesions on the skin, which can cause mutilations and social stigma, to visceral disease with severe manifestations, which is potentially fatal without treatment.

Due to the particular challenges and the scale of leishmaniasis, the new PAHO guidelines take into account evidence available in the region to provide recommendations and strengthen local systems for the treatment of the disease in its various clinical forms.

‘The Ministries of Health, through their respective technical areas and with the support of local experts, should revise the recommendations in the national context and determine the possibility of incorporating, guaranteeing and expanding patient access to treatment of leishmaniasis using safer and shorter-term therapeutic alternatives,’ explains Ana Nilce Silveira Maia-Elkhoury, Regional Advisor for Leishmaniasis, PAHO/WHO.

For the treatment of visceral leishmaniasis, the new guidelines now incorporate liposomal amphotericin B as a strong recommendation against the use of pentavalent antimonials. This treatment is more accessible for people because of its shorter duration, fewer side effects and reduced hospitalization time.

The change in first-line treatment is based on evidence generated by a collaborative study sponsored by the Brazilian Ministry of Health and coordinated by the University of Brasilia (UnB), the Oswaldo Cruz Foundation of Brazil (Fiocruz), and DNDi. The study assessed the efficacy and safety of different treatment options compared to the standard, antimonial-based treatment.

The LV Brasil study included the cooperative work of the Federal University of Piauí, State University of Montes Claros, Federal University of Sergipe, Hospital Infantil João Paulo II – Fundação Hospitalar do Estado de Minas Gerais, and Hospital São José de Doenças Infecciosas, from Fortaleza.

However, the full adoption of this recommendation in Brazil, the country with the highest number of visceral leishmaniasis cases in the Americas, requires coordinated efforts to address current drug supply issues, which are impacting people’s access to treatment. 

For cutaneous leishmaniasis, for patients with 1 to 3 lesions ≤3 cm in diameter, the new guidelines recommend the intralesional use of antimonials (strong recommendation) or thermotherapy (conditional recommendation). For patients requiring systemic treatment, the use of miltefosine (strong recommendation) or pentamidine (conditional recommendation and only for patients with lesions caused by L. guyanensis) is recommended.

‘These recommendations go hand in hand with DNDi’s strategy, which has promoted the need to replace antimonials as a first treatment option and recommend miltefosine instead, be it by itself or in combination with local therapies, which are safer for patients and less costly for health systems,’ said Joelle Rode, Clinical Manager for Leishmaniasis at DNDi Latin America.

In addition to the main risk factors resulting from social, economic, and environmental factors, which favour leishmaniasis transmission and hinder its control, patients under treatment face serious side effects of the medications. The disease also has devastating effects on communities, including work difficulties, economic losses, and social stigma in populations already living with limited resources.

The needs of these neglected populations guide DNDi’s strategy, which, in collaboration with the countries in the region, has been generating evidence on the safety and effectiveness of treatments for patients with visceral leishmaniasis and cutaneous leishmaniasis, seeking to improve existing treatment options. DNDi is currently studying a combination of an oral treatment with local heat application (or thermotherapy) for cutaneous leishmaniasis in four countries in the region to confirm preliminary results from our Phase II trial in Peru and Colombia, which showed positive outcomes combining thermotherapy and miltefosine compared to treatment with thermotherapy alone.

At the same time, DNDi continues its search for a new short course, oral treatment which is safe, effective, affordable, through international, multidisciplinary and innovative consortia. Some examples are Lead Optimization Latin America (LOLA), a structure-based drug discovery project for leishmaniasis, and a translational research project to find new tools to help with the clinical development of active molecules for cutaneous leishmaniasis. We are studying the development of an ‘immunomodulator’ that can stimulate the innate immune system to fight the problems caused by the cutaneous leishmaniasis parasites.

By advancing multiple strategies and building capacity in the Americas, DNDi hopes to identify new drugs to treat leishmaniasis in the next few years. At the same time, DNDi is urging health and regulatory authorities of the countries in the region to prioritize their drug procurement strategies and the internalization of these new treatment guidelines in order to guarantee greater access to treatment to the most vulnerable population.

About DNDi

The Drugs for Neglected Diseases initiative (DNDi) is a patient needs-driven, not-for-profit research and development (R&D) organization. Together with its partners, the initiative develops safe, effective and affordable treatments for millions of people affected by neglected tropical and viral diseases. Some of these diseases that disproportionately affect communities that are already vulnerable and neglected are Chagas disease, leishmaniasis, sleeping sickness, paediatric HIV, hepatitis C, filarial disease and mycetoma. DNDi aims to deliver a total of 25 new treatments in its first 25 years, by 2028. dndi.org

Media contacts

Marcela Dobarro
mdobarro@dndi.org
+55 21 981149429

Photo credit: Vinicius Berger-DNDi

Registration & access Visceral leishmaniasis Latin America

Read, watch, share

Loading...
Patient with healthcare worker in hospital
Press releases
30 Mar 2023

Eumycetoma: DNDi welcomes Japan’s GHIT Fund support for registration of new treatment for deeply neglected fungal disease

Davide Paparo and Ian Hausler with their thermotherapy device "CLARA"
Stories
16 Mar 2023

Cutaneous leishmaniasis: Swiss students develop innovative thermotherapy device for safer treatment of ‘flesh-eating parasite’

Stories
8 Mar 2023

Highlighting gender-based treatment gaps on International Women’s Day: Mary Alamak’s story

DNDi-GARDP Southern Africa director, Carol Ruffell (left), presents the December 2022 edition of HIV Nursing Matters and the 2022 paediatric ARV dosing chart to Bénédicte Schutz, Monaco’s Director of International Cooperation (centre), and Yordanos Pasquier, Monaco’s Deputy Director of International Cooperation (right).
News
3 Mar 2023

Working together to ensure optimal treatment for children living with HIV in South Africa

Nurse with patient
Press releases
1 Mar 2023

Fiocruz and DNDi sign strategic alliance agreement

Statements
28 Feb 2023

DNDi’s submission to the Technical Assessment component of the first Global Stocktake

Statements
22 Feb 2023

DNDi comments on the zero draft of the WHO CA+ for consideration of the Intergovernmental Negotiating Body at INB4 & 5

Hat Platform Newsletter N°22 screenshot
Publications
22 Feb 2023

HAT Platform Newsletter No. 22

VIEW ALL

Help neglected patients

To date, we have delivered twelve new treatments, saving millions of lives.

Our goal is to deliver 25 new treatments in our first 25 years. You can help us get there. 

GIVE NOW
DNDi - Best Science for the Most Neglected 20 Years
Facebook-f
Twitter
Instagram
Linkedin-in
Youtube
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • Neglected tropical diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License   
We use cookies to track our audience and improve our content. By clicking 'Accept All', you are agreeing to our use of cookies. Click on 'Customize' to accept only some cookies.
Customize
REJECT ACCEPT ALL
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-advertisement1 yearSet by the GDPR Cookie Consent plugin, this cookie is used to record the user consent for the cookies in the "Advertisement" category .
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
CookieLawInfoConsent1 yearRecords the default button state of the corresponding category & the status of CCPA. It works only in coordination with the primary cookie.
PHPSESSIDsessionThis cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
CookieDurationDescription
elementorneverThis cookie is used by the website's WordPress theme. It allows the website owner to implement or change the website's content in real-time.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
CookieDurationDescription
_ga2 yearsThe _ga cookie, installed by Google Analytics, calculates visitor, session and campaign data and also keeps track of site usage for the site's analytics report. The cookie stores information anonymously and assigns a randomly generated number to recognize unique visitors.
_ga_16Q5RH3XRG2 yearsThis cookie is installed by Google Analytics.
_gat_UA-10302561-11 minuteA variation of the _gat cookie set by Google Analytics and Google Tag Manager to allow website owners to track visitor behaviour and measure site performance. The pattern element in the name contains the unique identity number of the account or website it relates to.
_gid1 dayInstalled by Google Analytics, _gid cookie stores information on how visitors use a website, while also creating an analytics report of the website's performance. Some of the data that are collected include the number of visitors, their source, and the pages they visit anonymously.
_hjAbsoluteSessionInProgress30 minutesHotjar sets this cookie to detect the first pageview session of a user. This is a True/False flag set by the cookie.
_hjFirstSeen30 minutesHotjar sets this cookie to identify a new user’s first session. It stores a true/false value, indicating whether it was the first time Hotjar saw this user.
_hjIncludedInPageviewSample2 minutesHotjar sets this cookie to know whether a user is included in the data sampling defined by the site's pageview limit.
_hjIncludedInSessionSample2 minutesHotjar sets this cookie to know whether a user is included in the data sampling defined by the site's daily session limit.
_hjSession_112884430 minutesHotjar sets this cookie.
_hjSessionUser_11288441 yearHotjar sets this cookie.
CONSENT2 yearsYouTube sets this cookie via embedded youtube-videos and registers anonymous statistical data.
Targeting
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
SAVE & ACCEPT
Powered by CookieYes Logo